Finance

Beta
Lists
1MRK:BIT
Merck KGaA
€130.50
+0.31%
(+0.40) 1D
May 29, 5:28:17 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1MRK...
Open
€130.55
High
€130.80
Low
€130.50
Mkt. cap
56.89B
Avg. vol.
66.00
Volume
74.00
Dividend
1.69%
Quarterly dividend
€0.55
Ex-dividend date
Apr 27, 2026
P/E ratio
22.40
52-wk high
€136.30
52-wk low
€102.35
EPS
€5.83
No. of employees
62K
Open
€130.55
High
€130.80
Low
€130.50
Mkt. cap
56.89B
Avg. vol.
66.00
Volume
74.00
Dividend
1.69%
Quarterly dividend
€0.55
Ex-dividend date
Apr 27, 2026
P/E ratio
22.40
52-wk high
€136.30
52-wk low
€102.35
EPS
€5.83
No. of employees
62K
News stories
From sources across the web
Profile
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally. Merck operates in Europe, Africa, Asia, Oceania and the Americas. It has major research and development centres in Darmstadt, Boston, Shizuoka and Beijing, as well as other Research and Development units in Taiwan, France, Israel, South Korea, India, and the UK. Merck pioneered the commercial manufacture of morphine in the 19th century and for a time held a virtual monopoly on cocaine. Merck was privately owned until going public on the Frankfurt Stock Exchange in 1995 and is listed on the DAX index of Germany's top companies. The Merck family still controls a majority of 70.3% of the company's shares. Wikipedia
About Merck KGaA
CEO-
Employees62.5K
Founded1668
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.26B
5.32B
5.25B
5.13B
Cost of goods sold
2.23B
2.10B
2.20B
2.07B
Cost of revenue
2.23B
2.10B
2.20B
2.07B
Research and development expenses
539.00M
660.00M
634.00M
657.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.48B
1.46B
1.54B
1.52B
Operating expense
2.14B
1.99B
2.12B
2.13B
Total operating expenses
4.36B
4.10B
4.32B
4.20B
Operating income
891.00M
1.22B
926.00M
935.40M
Other non operating income
-
1.00M
4.00M
-100.00K
EBT including unusual items
829.00M
1.12B
401.00M
868.70M
EBT excluding unusual items
829.00M
1.12B
1.10B
867.50M
Income tax expense
174.00M
225.00M
77.00M
200.00M
Effective tax rate
20.99%
20.04%
19.20%
23.02%
Other operating expenses
121.00M
-128.00M
-50.00M
-45.40M
Net income
652.00M
902.00M
319.00M
659.40M
Net profit margin
12.41%
16.96%
6.08%
12.84%
Earnings per share
-
-
-
-
Interest and investment income
17.00M
27.00M
21.00M
21.20M
Interest expense
-79.00M
-126.00M
-43.00M
-80.60M
Net interest expenses
-62.00M
-99.00M
-22.00M
-59.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.32B
1.68B
1.31B
1.42B
Gain or loss from assets sale
-5.00M
-174.00M
6.00M
-41.90M
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more